Pharma Tech Transfer FAQs: Reducing Risk, Cost, and Delays in Scale-Up

Sofia Santos

Author

Sofia Santos

Product Strategist

ValGenesis

LinkedIn

Published on July 2, 2026
Reading time: -- minutes
Last updated on July 2, 2026
Reviewed by: Lisa Weeks

Summary

Tech transfer is where process knowledge gets proven in real manufacturing — moving from development to production, or across sites and partners — without losing quality or time.

It works best when sending and receiving teams stay coordinated, keep process knowledge complete and up to date, and treat the work as more than a document handoff.

Key Takeaways

  • Tech transfer slows down when knowledge is fragmented (paper/spreadsheets), expectations aren’t shared, or site/equipment/material differences aren’t handled early.

  • QbD makes transfers easier by giving the receiving unit clear CQAs/CPPs, design space, and control strategy to guide scale-up decisions.

  • Digital transfer environments help teams work from a single, current view of process knowledge and reduce rework caused by version drift.

Who is this for

  • Tech transfer and technology transfer project managers
  • MSAT (Manufacturing Science & Technology) teams
  • Process development scientists and process engineers
  • Manufacturing/operations leaders and manufacturing engineers
  • Quality assurance (QA) and quality control (QC) teams
  • CDMO/CMO program managers and external manufacturing leads
  • Regulatory CMC teams
featured image

Tech transfer is where process knowledge is tested under real-world conditions. As products move from development to manufacturing—or across sites and partners—teams must transfer complex process understanding without compromising quality or introducing delays.

In practice, that means coordinating across functions, aligning expectations between sending and receiving units, and ensuring that critical knowledge is not lost in translation. When done well, tech transfer enables faster scale-up and smoother commercialization. When done poorly, it can lead to rework, failed batches, and increased costs.

This FAQ addresses the most common questions life sciences teams ask about tech transfer, including scale-up challenges, digital transformation, and the role of structured knowledge in improving execution.

 

Understanding Tech Transfer in Pharma

What is tech transfer in pharma?
Tech transfer is the transfer of product and process knowledge between development and manufacturing, or within and between manufacturing sites, to achieve product realization.

When do companies usually need a tech transfer?
Three common scenarios include moving through lifecycle stages, adding manufacturing capacity, and transferring production to another site or partner, such as a CMO or CDMO.

Why is tech transfer so critical during scale-up?
Moving to a new scale or site changes equipment, materials, batch size, and infrastructure. The receiving unit needs a deep understanding of the process to maintain quality, safety, and efficacy.

 

Common Challenges and Failure Points in Tech Transfer

Why do tech transfers take so much time and money?
Tech transfers require large cross-functional teams, multiple tech and validation batches, and extensive coordination. Paper-based systems and non-standardized data packages add duplicate work, miscommunication, and rework.

What are the biggest failure modes in tech transfer?
Common issues include poor alignment between sending and receiving units, equipment mismatches, environmental differences, raw material variability, and weak knowledge transfer. These gaps can trigger nonconformities, failed batches, and repeated process runs.

Why do paper and spreadsheets create problems in tech transfer?
They make it difficult to maintain a single, current view of the process. Manual packages increase duplicate work, version drift, and delays as the receiving unit has to reconstruct the development story.

How does outsourcing to a CDMO change the transfer challenge?
Outsourcing adds complexity because the receiving party must fully understand the process while operating within a different organization’s systems, capabilities, and infrastructure.

What are common barriers to effective scale-up?
Barriers include new equipment, new materials, or supply chain conditions, changes in batch size, and the need to maintain quality at a site with different capabilities.

 

How Can Teams Improve Tech Transfer Outcomes?

What should I do first if I want a faster tech transfer?
Start by nominating a dedicated project management team to coordinate sending and receiving units, align expectations, and prevent execution from drifting across functions.

Why is a dedicated project team recommended for tech transfer?
Tech transfer involves manufacturing, QA, QC, regulatory, engineering, and development simultaneously. A dedicated team keeps decisions moving and reduces handoff risk.

How does QbD help a tech transfer or scale-up program?
QbD provides the receiving unit with a stronger understanding of CQAs, CPPs, design space, and control strategy. This enables more science-based scale-up decisions and reduces right-first-time errors.

What does a “single version of the truth” mean in tech transfer?
It means both sending and receiving teams work from the same current process knowledge, data, and rationale — an advantage enabled by digital transfer environments.

How can digital transformation improve tech transfer?
Digital transformation enables centralized knowledge, fewer manual handoffs, improved collaboration, and faster access to process information. This shortens transfer cycles and reduces avoidable errors.

How do digital tools support process scale-up?
They support process design, data sharing, risk-based decisions, and advanced control strategy development, giving teams a stronger foundation for scaling while maintaining control.

What digital capabilities are important for tech transfer?
Key capabilities include big data analytics, IoT, AI-enabled risk-based approaches, advanced control strategies, and robust knowledge management.

How does improved knowledge management help tech transfer?
It keeps process design, scale-up learnings, and control logic connected, reducing the need to rediscover key decisions when transferring to a new team or site.

What should I look for when assessing a CDMO’s digital capabilities?
Look for the ability to share structured process knowledge, support collaboration, and maintain digital continuity across transfer activities rather than relying on disconnected files.

How can better transfer execution reduce right-first-time problems?
A stronger strategy, better alignment, and shared digital knowledge reduce the risk of misinterpreting or losing process assumptions during handoffs, minimizing repeat work and failed batches.

What business impact does better tech transfer have?
Improved execution lowers costs, accelerates time to market, reduces right-first-time failures, and enables smoother industrialization.

What is the practical takeaway on tech transfer?
Tech transfer should be treated as a cross-functional, knowledge-intensive process —not just a document handoff. Dedicated ownership, QbD principles, and digital tools help keep scale-up decisions traceable and execution efficient.

As part of the broader process lifecycle, tech transfer plays a critical role in connecting development knowledge to commercial execution—making structured knowledge and digital continuity essential for consistent, scalable outcomes.

 

 

References

1

European Commission. (n.d.). https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en

EudraLex—Volume 4: EU guidelines for good manufacturing practice for medicinal products for human and veterinary use. Accessed Date: 28 April 2026.

2

European Medicines Agency. (2014). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-process-validation-finished-products-information-data-be-provided-regulatory_en.pdf

Guideline on process validation for finished products—Information and data to be provided in regulatory submissions (Revision 1). Accessed Date: 28 April 2026.

3

European Medicines Agency. (n.d.). https://www.ema.europa.eu/en/process-validation-finished-products

Process validation for finished products. Accessed Date: 28 April 2026.

4

Food and Drug Administration. (2011). https://www.fda.gov/media/71021/download

Process validation: General principles and practices. publication. Accessed Date: 28 November 2025.

5

Food and Drug Administration. (n.d.). https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations

Current good manufacturing practice (CGMP) regulations. publication. Accessed Date: 28 April 2026.

6

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). https://www.ich.org/page/quality-guidelines

ICH Q8, Q9, and Q10 guidelines. Accessed Date: 28 April 2026.

7

International Society for Pharmaceutical Engineering. (2019). https://ispe.org/publications/guidance-documents/good-practice-guide-technology-transfer-3rd-edition?

ISPE good practice guide: Technology transfer (3rd ed.). ISPE. Accessed Date: 28 April 2026.

8

Parenteral Drug Association. (2022). https://www.pda.org/bookstore/product-detail/6680-tr-65-revised-technology-transfer?

Technical report no. 65 (revised 2022): Technology transfer. PDA. Accessed Date: 28 April 2026.

9

Pharmaceutical Inspection Co-operation Scheme. (2021). https://picscheme.org/en/publications

Guide to good manufacturing practice for medicinal products (PE 009-17, Part I). Accessed Date: 28 April 2026.

10

United States Pharmacopeia. (n.d.). https://doi.usp.org/USPNF/USPNF_M10975_02_01.html?utm_

USP general chapter <1220> analytical procedure life cycle. USP. Accessed Date: 28 April 2026.

11

World Health Organization. (2014). https://www.who.int/publications/m/item/trs-986-annex-02

WHO good manufacturing practices for pharmaceutical products: Main principles (WHO Technical Report Series No. 986, Annex 2). Accessed Date: 28 April 2026.

The opinions, information and conclusions contained within this blog should not be construed as conclusive fact, ValGenesis offering advice, nor as an indication of future results.

Related Blog Posts